The Changes of Cholesterol Profile at the Different Insulin Resistance Range in the Czech Republic
Abstract
:1. Introduction
2. Materials and Methods
2.1. Parameters for Evaluation
2.2. Patients and Samples
2.3. Laboratory Analysis
2.4. Statistical Analysis
3. Results
4. Statistical Analysis
5. Discussion
6. Limitations of the Study
7. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Parhofer, K.G. Interaction between glucose and lipid metabolism: More than diabetic dyslipidemia. Diabetes Metab. J. 2015, 39, 353–362. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zheng, S.; Xu, H.; Zhou, H.; Ren, X.; Han, T.; Chen, Y.; Qiu, H.; Wu, P.; Zheng, J.; Wang, L.; et al. Associations of lipid profiles with insulin resistance and β cell function in adults with normal glucose tolerance and different categories of impaired glucose regulation. PLoS ONE 2017, 12, e0172221. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bardini, G.; Rotella, C.M.; Giannini, S. Dyslipidemia and diabetes: Reciprocal impact of impaired lipid metabolism and beta-cell dysfunction on micro- and macrovascular complications. Rev. Diabet. Stud. 2012, 9, 82–93. [Google Scholar] [CrossRef] [PubMed]
- Ikeoka, D.; Krusinova, E. Insulin resistance and lipid metabolism. Rev. Assoc. Med. Bras. 2009, 55, 229–250. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Díaz-Ruiz, M.; Martínez-Triguerob, M.; López-Ruizc, A.; Fernández-de la Cruzb, F.; Bañuls, C.; Hernández-Mijaresd, A. Metabolic disorders and inflammation are associated with familial combined hyperlipemia. Clin. Chim. Acta 2019, 490, 194–199. [Google Scholar]
- Nagel, J.M.; Tietz, A.B.; Burkhard, G.; Parhofer, K.G. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metab. Clin. Exp. 2006, 55, 1149–1154. [Google Scholar] [CrossRef] [PubMed]
- Furuhashi, M.; Ura, N.; Nakata, T.; Shimamoto, K. Insulin sensitivity and lipid metabolism in human CD 36 deficiency. Diabetes Care 2003, 26, 471–474. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turneer, R.C. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28, 412–419. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Karen, I.; Svačina, Š. Diabetes Mellitus v Primární Péči—2. Rozšířené Vydání (Diabetes Mellitus in Primary Care—Second Issue); Axonite: Prague, Czech Republic, 2014. [Google Scholar]
- Horáková, D.; Štěpánek, L.; Janout, V.; Janoutová, J.; Pastucha, D.; Kollárová, H.; Petráková, A.; Štěpánek, L.; Husár, R.; Martiník, K. Optimal homeostasis model assessment of insulin resistance (HOMA-IR) cut-off in Czech population. Medicina 2019, 55, 158. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, H.H.; Garruti, G.; Liu, M.; Portincasa, P.; Wang, D.Q. Cholesterol and lipoprotein metabolism and atherosclerosis: Recent advances in reverse cholesterol transport. Ann. Hepatol. 2017, 16, 27–42. [Google Scholar] [CrossRef] [PubMed]
- Aye, M.M.; Butler, A.E.; Kilpatrick, E.S.; Kirk, R.; Vince, R.; Rigby, A.S.; Sandeman, D.; Atkin, S.L. Dynamic change in insulin resistance induced by free fatty acids is unchanged though insulin sensitivity improves following endurance exercise in PCOS. Front. Endocrinol. 2018, 5, 592. [Google Scholar] [CrossRef] [PubMed]
- Zvára, K.; Štěpán, J. Pravděpodobnost a Matematická Statistika (Probability and Mathematical Statistics); Matfyzpress: Prague, Czech Republic, 2001. [Google Scholar]
- Friedecký, B.; Kratochvíla, J.; Springer, D.; Prázný, M.; Zima, T. Diabetes Mellitus—Laboratorní Diagnostika a Sledování Stavu Pacientů (Diabetes Mellitus—Laboratory Diagnostics and Monitoring of Patients); ČDS & ČSKB: Prague, Czech Republic, 2016. [Google Scholar]
- Mora, S.; Kamstrup, P.R.; Rifai, N.; Nordestgaard, B.G.; Buring, J.E.; Ridker, P.M. Lipoprotein(a) and risk of type 2 diabetes. Clin. Chem. 2010, 56, 1252–1260. [Google Scholar] [CrossRef] [PubMed]
- Day, C. Metabolic syndrome or what you will: Definitions and epidemiology. Diab. Vasc. Dis. Res. 2007, 4, 32–38. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Toro-Huamanchumo, C.J.; Urrunaga-Pastor, D.; Guarnizo-Poma, M.; Lazaro-Alcantara, H.; Paico-Palacios, S.; Pantoja-Torres, B.; del Carmen Ranilla-Seguin, V.; Benites-Zapata, V. Triglycerides and glucose index as an insulin resistance marker in a sample of healthy adults. Diabetes Metab. Syndr. 2019, 13, 272–277. [Google Scholar] [CrossRef] [PubMed]
- Keska, A.; Lutoslawska, G.; Czajkowska, A.; Tkaczyk, J.; Mazurek, K. Variability in HOMA-IR, lipoprotein profile and selected hormones in young active men. Sci. World J. 2013, 2, 412764. [Google Scholar] [CrossRef] [PubMed]
- Lee, C.H.; Shih, A.Z.L.; Woo, Y.C.; Fong, C.H.Y.; Leung, O.Y.; Janus, E.; Cheung, B.M.Y.; Lam, K.S.L. Optimal cut-offs of homeostasis model assessment of insulin resistance (HOMA-IR) to identify dysglycemia and type 2 diabetes mellitus: A 15-year prospective study in Chinese. PLoS ONE 2016, 11, e0163424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shalaurova, I.; Connelly, M.A.; Garvey, W.T.; Otvos, J.D. Lipoprotein insulin resistance index: A lipoprotein particle-derived measure of insulin resistance. Metab. Syndr. Relat. Disord. 2014, 12, 422–429. [Google Scholar] [CrossRef] [PubMed]
- Notsu, Y.; Nabika, T.; Shibata, H.; Nagai, A.; Shiwaku, K.; Masuda, J. HOMA-IR and related clinical parameters. Rinsho Byori. 2007, 55, 737–742. [Google Scholar] [PubMed]
Characteristics | Age (y) | Glucose (mmol/L) | Insulin (mIU/L) | Total Cholesterol (mmol/L) | HDL Cholesterol (mmol/L) | LDL Cholesterol (mmol/L) | HOMA IR |
---|---|---|---|---|---|---|---|
N | 2627 | 2627 | 2627 | 2627 | 2627 | 2627 | 2627 |
40.3 | 5.3 | 6.7 | 5.1 | 1.5 | 3.0 | 1.6 | |
11.5 | 0.6 | 3.5 | 1.0 | 0.4 | 0.9 | 0.8 | |
Σ | 132.9 | 0.3 | 11.9 | 1.0 | 0.2 | 0.8 | 0.7 |
Min | 15.0 | 3.3 | 0.6 | 2.3 | 0.6 | 0.5 | 0.1 |
Max | 78.0 | 8.7 | 19.4 | 10.3 | 3.8 | 7.2 | 3.63 |
Characteristics | Age (y) | Glucose (mmol/L) | Insulin (mIU/L) | Total Cholesterol (mmol/L) | HDL Cholesterol (mmol/L) | LDL Cholesterol (mmol/L) | HOMA IR |
---|---|---|---|---|---|---|---|
N | 424 | 424 | 424 | 424 | 424 | 424 | 424 |
41.5 | 5.9 | 39.8 | 5.1 | 1.2 | 3.2 | 10.1 | |
12.6 | 1.0 | 68.9 | 1.0 | 0.3 | 0.9 | 16.9 | |
Σ | 159.4 | 0.9 | 4749.2 | 1.0 | 0.1 | 0.8 | 284.2 |
Min | 15.0 | 4.0 | 11.5 | 2.7 | 0.6 | 0.75 | 3.6 |
Max | 73.0 | 18.0 | 309.0 | 8.7 | 2.5 | 6.1 | 93.4 |
Characteristics | Age (y) | Glucose (mmol/L) | Insulin (mIU/L) | Cholesterols (mmol/L) | HOMA IR | ||
---|---|---|---|---|---|---|---|
Total | HDL | LDL | |||||
Subjects with HOMA IR ≤ 3.63 | 40.3 | 5.3 | 6.7 | 5.1 | 1.5 | 3.0 | 1.6 |
Subjects with HOMA IR > 3.63 | 41.5 | 5.9 | 39.8 | 5.1 | 1.2 | 3.2 | 10.1 |
Optimal range of values [9,14] | - | 3.9–5.6 | 2.5–24.0 | 2.9–5.0 | 1.0–2.1 | 1.2–3 | <3.63 |
Glucose (mmol/L) | |||||
Subjects with HOMA IR | Lower whisker | Q1 | Median | Q3 | Upper whisker |
≤3.63 | 4.2 | 5.0 | 5.3 | 5.7 | 6.6 |
>3.63 | 4.5 | 5.4 | 5.8 | 6.3 | 7.4 |
Insulin (mIU/L) | |||||
Subjects with HOMA IR | Lower whisker | Q1 | Median | Q3 | Upper whisker |
≤3.63 | 2.00 | 4.0 | 6.0 | 9.0 | 14.8 |
>3.63 | 13.2 | 16.5 | 19.7 | 26.8 | 309.0 |
HOMA IR | |||||
Subjects with HOMA IR | Lower whisker | Q1 | Median | Q3 | Upper whisker |
≤3.63 | 0.4 | 0.9 | 1.4 | 2.1 | 3.5 |
>3.63 | 3.7 | 4.2 | 5.1 | 7.0 | 78.3 |
LDL (mmol/L) | |||||
Subjects with HOMA IR | Lower whisker | Q1 | Median | Q3 | Upper whisker |
≤3.63 | 1.4 | 2.4 | 2.9 | 3.5 | 5.0 |
>3.63 | 1.6 | 2.6 | 3.1 | 3.8 | 5.2 |
HDL (mmol/L) | |||||
Subjects with HOMA IR | Lower whisker | Q1 | Median | Q3 | Upper whisker |
≤3.63 | 0.8 | 1.2 | 1.5 | 1.8 | 2.5 |
>3.63 | 0.7 | 1.0 | 1.2 | 1.4 | 2.1 |
Total cholesterol (mmol/L) | |||||
Subjects with HOMA IR | Lower whisker | Q1 | Median | Q3 | Upper whisker |
≤3.63 | 3.3 | 4.4 | 5.1 | 5.7 | 10.3 |
>3.63 | 3.2 | 4.4 | 5.0 | 5.7 | 8.7 |
Parameter | Total Cholesterol (mmol/L) | HDL Cholesterol (mmol/L) | LDL Cholesterol (mmol/L) |
---|---|---|---|
F critical value (p = 0.05) | 0.89 | 0.89 | 0.89 |
p-value | 0.005 | 0.006 | 0.004 |
F-test | 0.956 * | 1.621 * | 0.946 * |
Parameter | Total Cholesterol (mmol/L) | HDL Cholesterol (mmol/L) | LDL Cholesterol (mmol/L) |
---|---|---|---|
T critical value (p = 0.05) | 1.96 | 1.96 | 1.96 |
p-value | 0.96 | 0.00001 | 0.00002 |
T test | 0.51 | 13.86 ** | 4.77 ** |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kron, V.; Verner, M.; Smetana, P.; Horáková, D.; Šlégr, J.; Studnička, F.; Bušovský, D.; Martiník, K. The Changes of Cholesterol Profile at the Different Insulin Resistance Range in the Czech Republic. Medicina 2021, 57, 249. https://doi.org/10.3390/medicina57030249
Kron V, Verner M, Smetana P, Horáková D, Šlégr J, Studnička F, Bušovský D, Martiník K. The Changes of Cholesterol Profile at the Different Insulin Resistance Range in the Czech Republic. Medicina. 2021; 57(3):249. https://doi.org/10.3390/medicina57030249
Chicago/Turabian StyleKron, Vladimír, Miroslav Verner, Pavel Smetana, Dagmar Horáková, Jan Šlégr, Filip Studnička, Damián Bušovský, and Karel Martiník. 2021. "The Changes of Cholesterol Profile at the Different Insulin Resistance Range in the Czech Republic" Medicina 57, no. 3: 249. https://doi.org/10.3390/medicina57030249
APA StyleKron, V., Verner, M., Smetana, P., Horáková, D., Šlégr, J., Studnička, F., Bušovský, D., & Martiník, K. (2021). The Changes of Cholesterol Profile at the Different Insulin Resistance Range in the Czech Republic. Medicina, 57(3), 249. https://doi.org/10.3390/medicina57030249